Subscribe
istock-ciphotos-istockphoto-com665048016-1-
CIPhotos / iStockphoto.com
31 January 2019Americas

Celgene signs $1bn deal to develop blood cancer therapy

Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.

More on this story

Big Pharma
Celgene settles antitrust class-action for $55m
25 July 2019   US biotech company Celgene has agreed to pay a $55 million settlement after it was accused of illegally maintaining a monopoly over the market for its cancer treatments.
Americas
Celgene reveals plans to acquire Juno for $9bn
23 January 2018   Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.

More features

Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team